|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
1/2025
vol. 100 abstract:
Case report
Optimal management strategies for paediatric morphea – insights from a case series
Kinga Łagosz
1
,
Natalia Bień
1
,
Justyna Ceryn
1
,
Paulina Barsińska
1
,
Dorota Sobolewska-Sztychny
1
,
Joanna Narbutt
1
,
Aleksandra Lesiak
1, 2
Pediatr Pol 2025; 100 (1): 92-96
Online publish date: 2025/03/24
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Juvenile localized scleroderma, or morphea, is a rare chronic inflammatory disease primarily affecting the skin and subcutaneous tissue. Treatment options for paediatric cases are diverse, with a lack of standardised guidelines. This case series investigates the efficacy of systemic therapy combining methotrexate (MTX) and oral prednisone in children diagnosed with linear scleroderma. Seven paediatric patients diagnosed with linear scleroderma received systemic treatment consisting of MTX alongside oral prednisone. Clinical evaluation focused on monitoring disease progression and assessing improvements in skin manifestations. All patients demonstrated effective suppression of disease progression and gradual enhancement in skin condition following treatment initiation with MTX e and oral prednisone. This combined systemic therapy shows promising efficacy in halting disease advancement and improving skin manifestations in children with linear scleroderma. These findings underscore the potential benefit of this treatment approach in managing juvenile localised scleroderma; however, further research is necessary to establish comprehensive therapeutic guidelines.
keywords:
morphea, juvenile localised scleroderma, methotrexate, children, treatment |
POLSKI
